Literature DB >> 30799782

Adverse Effects of Mineralocorticoid Receptor Antagonist Administration.

Manolis S Kallistratos1, Andreas Pittaras1, Iakovos Theodoulidis2, Charris Grassos3, Leonidas E Poulimenos1, Athanasios J Manolis1,4.   

Abstract

BACKGROUND: Mineralocorticoid receptor antagonists consist of a class of drugs with pleiotropic beneficial effects in several cardiovascular diseases. However, physicians frequently overlook their use due to the adverse effects of such agents.
OBJECTIVES: To determine the adverse effects of mineralocorticoid receptor antagonists and to suggest clinically meaningful options. We present data on the two most administered agents of this class: spironolactone and eplerenone.
METHOD: We conducted an in-depth review of the existing international literature to draft a mini review about the mineralocorticoid receptor antagonists-related side effects. RESULT: Mineralocorticoid receptor antagonists are associated with increased risk of hyperkalemia and acute deterioration of renal function. Of note, these adverse effects are dose-dependent, more common during the initial period of treatment, and are usually reversed after the withdrawal of therapy. Sex-related adverse events are noted mainly in spironolactone while switching to eplerenone could attenuate those.
CONCLUSION: Mineralocorticoid receptor antagonists therapy is significantly limited due to their side effects. The development of novel non-steroidal mineralocorticoid receptor antagonists could substantially widen the use of such agents. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Mineralocorticoid receptor antagonist; acute kidney injury; adverse event; eplerenone; hyperkalemia; spironolactone.

Year:  2018        PMID: 30799782     DOI: 10.2174/1381612825666190222144359

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  3 in total

1.  Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats.

Authors:  Asadur Rahman; Tatsuya Sawano; Anupoma Sen; Akram Hossain; Nourin Jahan; Hideki Kobara; Tsutomu Masaki; Shinji Kosaka; Kento Kitada; Daisuke Nakano; Takeshi Imamura; Hiroyuki Ohsaki; Akira Nishiyama
Journal:  Int J Mol Sci       Date:  2021-02-19       Impact factor: 5.923

2.  Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers.

Authors:  Tadakatsu Nakamura; Atsuhiro Kawaguchi
Journal:  Clin Pharmacol Drug Dev       Date:  2020-08-20

Review 3.  The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers.

Authors:  Yuta Tezuka; Sadayoshi Ito
Journal:  Curr Hypertens Rep       Date:  2022-04-30       Impact factor: 4.592

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.